Eleven Biotherapeutics Lands $20,000,010 New Financing Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=45d28fee-c244-4e71-8d0b-d34ef78a0e7e
Date 12/8/2014
Company Name Eleven Biotherapeutics
Mailing Address 215 First Street Cambridge, MA 02142 USA
Company Description Eleven Biotherapeutics (NASDAQ: EBIO) uses its proprietary technology platform to create first-of-a-kind protein therapeutics to treat ocular diseases in new and effective ways.
Proceeds Purposes Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.